12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

Roche said in its 3Q12 earnings that in October FDA granted Priority Review to an sBLA from its Genentech unit for Avastin bevacizumab in combination with 5-FU-based chemotherapy as second-line therapy for metastatic colorectal cancer (mCRC) in patients who progressed on first-line therapy with...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >